Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not

[en] OBJECTIVE: To study the levels of matrix metalloproteinase-3 (MMP-3) in the knee synovial fluid (SF) of inflammatory arthropathies (rheumatoid arthritis whether erosive or not, reactive arthritis, acute crystal arthritis) and degenerative arthropathies [chronic crystal disease, osteoarthritis and (control) meniscus pathology] and to correlate them with the degree of joint destruction, local inflammatory and immune parameters and systemic markers of inflammation. METHODS: SF levels of MMP-3 (precursor, active and tissue inhibitor of MMP-bound forms), tumour necrosis factor (TNF) alpha, soluble TNF receptors I and II, interleukin (IL)-6 and soluble IL-6 receptor were measured by ELISA in 107 inflammatory and 53 degenerative arthropathies. RESULTS: MMP-3 levels in SF were (i) significantly higher in inflammatory than in degenerative arthropathies; (ii) not related to the degree of joint destruction; (iii) significantly correlated with the levels of all SF markers tested and with erythrocyte sedimentation rate and serum levels of C-reactive protein and fibrinogen. CONCLUSION: Increased MMP-3 levels in SF are found in inflammatory arthropathies and are not specific for erosive joint diseases. MMP-3 in SF is therefore a potential candidate for the assessment of the inflammatory process in joints. However, the exclusive determination of the active form could indicate the degree of joint destruction.

Disciplines :

Rheumatology

Author, co-author :

Ribbens, Clio ; Université de Liège - ULiège > Rhumatologie

Andre, Béatrice ; Université de Liège - ULiège > Rhumatologie - Néphrologie

Kaye, O.

Kaiser, M. J.

Bonnet, V.

Jaspar, J. M.

de Groote, D.

Franchimont, N.

Malaise, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie

Language :

English

Title :

Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not

Publication date :

2000

Journal title :

Rheumatology

ISSN :

1462-0324

eISSN :

1462-0332

Publisher :

Oxford University Press, Oxford, United Kingdom

Volume :

Issue :

Pages :

1357-1365

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 29 June 2011

Statistics

Number of views

61 (7 by ULiège)

Number of downloads

3 (3 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Walakowits LA, Moore VL, Bhardwaj N, Gallick GS, Lark MW. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and post traumatic knee injury. Arthritis Rheum 1992;35:35-42.
Kolkenbrock H, Hecker-Kia A, Orgel D et al. A trypsin sensitive stromelysin isolated from rheumatoid synovial fluid is an activator for matrix metalloproteinases. Eur J Clin Chem Clin Biochem 1993;31:625-31.
Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T. Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 1994;13:228-33.
Zucker S, Lysik RM, Zarrabi MH et al. Elevated plasma stromelysin levels in arthritis. J Rheumatol 1994; 21:2329-33.
Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M. Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995;38:969-75.
Manicourt DH, Fujimoto N, Obata K, Thonar EJMA. Levels of circulating collagenase, stromelysin-1 and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Arthritis Rheum 1995;38:1031-9.
Taylor DJ, Cheung NT, Dawes PT. Increased serum proMMP-3 in inflammatory arthritides: a potential indicator of synovial inflammatory monokine activity. Ann Rheum Dis 1994;53:768-72.
Ishiguro N, Ito T, Obata KI, Jujimoto N, Iwata H. Determination of stromelysin-1 72 and 92 kDA Type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J Rheumatol 1996; 23:1599-604.
Ichikawa Y, Yamada C, Horiki T, Hoshina Y, Uchiyama M. Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis. Clin Exp Rheumatol 1998; 16:533-40.
Keyszer G, Lambiri I, Nagel R et al. Circulating levels of metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J Rheumatol 1999;26:251-8.
Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor-α (cA2) therapy. Br J Rheumatol 1997;36:643-50.
So A, Chamot AM, Péclat V, Gerster JC. Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. Rheumatology 1999; 38:407-10.
Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993;36:181-9.
Ishiguro N, Ito T, Miyazaki K, Iwata H. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1999;26:34-40.
Cheung NT, Mattey DL, Dawes PT, Taylor DJ. Serum pro-matrix metalloproteinase 3 in rheumatoid arthritis: a reflection of local or systemic inflammation? [letter] Arthritis Rheum 1996;39:884.
Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977;18:481-91.
Steiner G, Studnicka-Benke A, Witzmann G, Hofler E, Smolen J. Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis. J Rheumatol 1995;22:406-12.
Altman RD. Criteria for classification of clinical osteoarthritis. J Rheumatol 1991;18(Suppl.)27:10-2.
Ribbens C, Andre B, Jaspar JM et al. Matrix metalloproteinase 3 serum levels are correlated with the disease activity and predict the clinical response in rheumatoid arthritis. J Rheumatol 2000;27:888-93.
Manicourt DH, Fujimoto N, Obata K, Thonar EJMA. Serum levels of collagenase, stromelysin-1 and TIMP-1. Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis. Arthritis Rheum 1994;37:1774-83.
Cholvy H, Combe B, Jaspar J-M, Vrindts Y, Sany J, Malaise M. Stromelysin-1 serum levels in rheumatoid arthritis: association with articular severity [abstract]. Arthritis Rheum 1997;40(Suppl.):S150.
Posthumus MD, Limburg PC, Westra J, Cats HA, Stewart RE, van Leeuwen MA et al. Serum levels of matrix metalloproteinase 3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology 1999;38:1081-7.
Mattey DL, Dawes PT, Cheung NP. Circulating levels of matrix metalloproteinases in rheumatic diseases [letter]. J Rheumatol 1999;26:2282-3.
Beekman B, van El B, Drijfhout JW, Ronday HK, TeKoppele JM. Highly increased level of active stromelysin in rheumatoid arthritis synovial fluid determined by a selective fluorogenic assay. FEBS Lett 1997;418:305-9.
Castell JV, Gomez-Lechon MJ, David M et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989; 242:237-9.
Miltenburg AMM, van Laar JM, de Kuiper R, Daha MR, Breedveld FC. Correlations of SF IL-6 levels with laboratory parameters of inflammation. Br J Rheumatol 1991;30:186-9.
Holt I, Cooper RG, Hopkins SJ. Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Invest 1991;21:479-84.
Brozik M, Rosztoczy I, Meretey K et al. Interleukin-6 levels in synovial fluids of patients with different arthritides: correlation with local IgM rheumatoid factor and systemic acute phase protein production. J Rheumatol 1992;19:63-8.
Badolato R, Oppenheim J. Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum 1996;26:526-38.
MacNaul KL, Chartrain N, Lark M, Tocci MJ, Hutchinson NI. Discoordinate expression of stromelysin, collagenase and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. J Biol Chem 1990;265:17238-45.
Vincenti MP, Clark JM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum 1994;37:1115-26.
Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin 6 in vitro. J Clin Invest 1989;83:585-92.
Ito A, Ito Y, Sasaguri Y, Norimatsu M, Mori Y. Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum 1992;35:1197-201.
Cope AP, Aderka D, Doherty M et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992;35:1160-9.
Roux-Lombard P, Punzi L, Hasler F et al. Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum 1993;36:485-9.
Partsch G, Steiner G, Leeb BF, Dunky A, Bröll H, Smolen JS. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997;24:518-23.
Partsch G, Wagner E, Leeb BF, Dunky A, Steiner G, Smolen J. Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. J Rheumatol 1998;25:105-10.
Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis. J Haematol 1995;54:1-8.
Feldmann M, Eliott MJ, Woody JN, Maini RN. Antitumor necrosis factor-α therapy of rheumatoid arthritis. Adv Immunol 1997;64:283-350.
Neidel J, Schulze M, Lindschau J. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis. Inflamm Res 1995;44:217-21.
Dayer JM, Fenner H. The role of cytokines and their inhibitors in arthritis. Baillière's Clin Rheumatol 1992; 6:485-516.
Girardin E, Roux-Lombard P, Grau GE et al. Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 1992;76:20-3.
van Leeuwen MA, van Rijswijk MH, Sluiter WJ et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997;24:20-7.
Palmer DG. Total leukocyte enumeration in pathologic synovial fluids. Am J Clin Pathol 1968;49:812-4.
Houssiau FA, Devogelaer JP, van Damme J, Nagant de Deuxchaisnes C, van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31:784-8.
van Leeuwen MA, Westra J, Limburg PC, van Riel PL, van Rijswijk MH. Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid arthritis. Ann Rheum Dis 1995;54:33-8.
Troughton PR, Platt R, Bird H, el-Manzalawi E, Bassiouni M, Wright V. Synovial fluid interleukin-8 and neutrophil function in rheumatoid arthritis and seronegative polyarthritis. Br J Rheumatol 1996;35: 1244-51.
McDonnel J, Hoerrner LA, Lark MW et al. Recombinant human interleukin-1-β-induced increase in levels of proteoglycans, stromelysin, and leukocytes in rabbit synovial fluid. Arthritis Rheum 1992;35:799-805.
Gabay CEM, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448-54.
Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 1989;8:3773-9.
Mackiewicz A, Speroff T, Ganapathi MK, Kushner I. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 1991;146:3032-7.
Arvidson NG, Gudbjornsson B, Elfman L, Ryden AC, Totterman TH, Hallgren R. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994;53:521-4.